Literature DB >> 6114005

Islet secretion in a new experimental model for non-insulin-dependent diabetes.

G C Weir, E T Clore, C J Zmachinski, S Bonner-Weir.   

Abstract

An animal model of diabetes mellitus has been developed in which neonatal rats are injected with streptozotocin at 2 days of age. After transient hyperglycemia followed by near normal glycemia, these animals develop nonketotic diabetes at about 6 wk of age that does not require insulin treatment. Secretion form the endocrine pancreas of 6-15-wk-old rats was evaluated with the isolated, perfused pancreas technique. Insulin secretion responded very poorly to high perfusate glucose concentrations, but in the presence of theophylline this meager response was enhanced. In contrast, arginine elicited an insulin response comparable to that of the control rats. Isoproterenol stimulated insulin secretion more in the diabetic model than in the controls, and tolbutamide failed to evoke insulin secretion. Glucagon secretion in response to arginine and isoproterenol was similar in both groups, but was suppressed less efficiently be glucose in the model than in controls. Evidence for enhanced basal secretion of somatostatin was also found. Thus, these hyperglycemic rats have a selective defect in glucose-stimulated insulin secretion with preservation of responses to other agents. In addition, abnormalities in the secretion of glucagon and somatostatin have been found.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114005     DOI: 10.2337/diab.30.7.590

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  51 in total

Review 1.  Cardiomyopathy associated with noninsulin-dependent diabetes.

Authors:  S W Schaffer
Journal:  Mol Cell Biochem       Date:  1991-09-18       Impact factor: 3.396

2.  B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia.

Authors:  V Grill; M Westberg; C G Ostenson
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

3.  Modulation of proinsulin messenger RNA after partial pancreatectomy in rats. Relationships to glucose homeostasis.

Authors:  M J Orland; R Chyn; M A Permutt
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

4.  The life story of the pancreatic B cell.

Authors:  C Hellerström
Journal:  Diabetologia       Date:  1984-06       Impact factor: 10.122

5.  Impaired growth hormone response to human pancreatic growth hormone releasing factor [GRF(1-44)] in type 2 (non-insulin-dependent) diabetes.

Authors:  N T Richards; S M Wood; N D Christofides; S C Bhuttacharji; S R Bloom
Journal:  Diabetologia       Date:  1984-11       Impact factor: 10.122

6.  Physiologic and cellular insulin action in a glucose-intolerant model of type 2 (non-insulin-dependent) diabetes in rats.

Authors:  B L Maloff; B K Boyd
Journal:  Diabetologia       Date:  1986-05       Impact factor: 10.122

7.  A rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced type 2 diabetes.

Authors:  Tsui-Wei Chou; Chien-Ya Ma; Hsing-Hsien Cheng; Ya-Yen Chen; Ming-Hoang Lai
Journal:  J Clin Biochem Nutr       Date:  2009-06-30       Impact factor: 3.114

8.  An in vivo analysis of pancreatic protein and insulin biosynthesis in a rat model for non-insulin-dependent diabetes.

Authors:  M A Permutt; K Kakita; P Malinas; I Karl; S Bonner-Weir; G Weir; S J Giddings
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

9.  Beta-cell dysfunction in hyperglycaemic rat models: recovery of glucose-induced insulin secretion with lowering of the ambient glucose level.

Authors:  J L Leahy; G C Weir
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

10.  Insulin resistance and mechanical dysfunction in hearts of Wistar rats with streptozotocin-induced non-insulin-dependent diabetes mellitus.

Authors:  S W Schaffer; G L Wilson
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.